三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01530)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025

FINANCIAL HIGHLIGHTS*

- Revenue decreased by RMB33.9 million or 0.8% to RMB4,355.5 million, as compared to the six months ended 30 June 2024.
- Gross profit decreased by RMB81.6 million or 2.1% to RMB3,715.8 million, as compared to the six months ended 30 June 2024. The gross profit margin decreased to 85.3% from 86.5% for the six months ended 30 June 2024.
- Net profit attributable to owners of the parent increased by RMB268.3 million or 24.6% to RMB1,358.2 million, as compared to the six months ended 30 June 2024. Net profit attributable to owners of the parent adjusted for non-operating items[1] increased by RMB23.4 million or 2.1% to RMB1,135.8 million, as compared to the six months ended 30 June 2024.
- EBITDA increased by RMB191.0 million or 11.6% to RMB1,832.5 million, as compared to the six months ended 30 June 2024. EBITDA adjusted for non-operating items[2] decreased by RMB53.8 million or 3.2% to RMB1,610.1 million, as compared to the six months ended 30 June 2024.

* All numbers in the "Financial Highlights" section are subject to rounding adjustments and therefore are approximate numbers only.

Notes:

1 The net profit attributable to owners of the parent adjusted for non-operating items is defined as the profit attributable to owners of the parent for the period excluding, as applicable (such excluded items, as applicable, "**Excluded Items**"): (a) the expenses associated with the awarded shares granted by 3SBio Inc. ("**3SBio**" or the "**Company**") in September 2024; (b) the expenses associated with the awarded shares granted under a restricted share incentive plan by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("**Sunshine Guojian**"), an indirect non-wholly owned subsidiary of 3SBio, in July 2024; (c) fair value gains or losses on financial assets at fair value through profit or loss ("**FVTPL**"); and (d) non-operating foreign exchange gains or losses.

2 The EBITDA adjusted for non-operating items is defined as the EBITDA for the period excluding the Excluded Items.

INTERIM RESULTS

The board (the "**Board**") of directors (the "**Directors**") of 3SBio is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries (collectively, the "**Group**") for the six months ended 30 June 2025 (the "**Reporting Period**"), together with the comparative figures for the corresponding period in 2024 as follows:

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2025

	Notes	**2025 (Unaudited) *RMB'000***	2024 (Unaudited) *RMB'000*
REVENUE	*4*	**4,355,485**	4,389,445
Cost of sales		**(639,680)**	(592,052)
Gross profit		**3,715,805**	3,797,393
Other income and gains	*5*	**408,289**	86,144
Selling and distribution expenses		**(1,615,934)**	(1,593,979)
Administrative expenses		**(283,402)**	(201,196)
Research and development costs		**(547,523)**	(476,230)
Other expenses	*6*	**(25,466)**	(40,687)
Finance costs	*7*	**(53,002)**	(104,351)
Share of profits and losses of:			
A joint venture		**1,315**	(814)
Associates		**21,615**	(44,412)
PROFIT BEFORE TAX		**1,621,697**	1,421,868
Income tax expense	*8*	**(233,123)**	(314,283)
PROFIT FOR THE PERIOD		**1,388,574**	1,107,585
Attributable to:			
Owners of the parent		**1,358,204**	1,089,942
Non-controlling interests		**30,370**	17,643
		1,388,574	1,107,585
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
— Basic	*10*	**RMB0.57**	RMB0.45
— Diluted	*10*	**RMB0.56**	RMB0.45

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2025

	2025 (Unaudited) *RMB'000*	2024 (Unaudited) *RMB'000*
PROFIT FOR THE PERIOD	**1,388,574**	1,107,585
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences:		
Exchange differences on translation of foreign operations	**(45,640)**	6,389
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods	**(45,640)**	6,389
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:		
Equity investments designated at fair value through other comprehensive income:		
Changes in fair value	**31,496**	48,473
Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods	**31,496**	48,473
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	**(14,144)**	54,862
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**1,374,430**	1,162,447
Attributable to:		
Owners of the parent	**1,344,060**	1,144,804
Non-controlling interests	**30,370**	17,643
	1,374,430	1,162,447

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2025

	Notes	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
NON-CURRENT ASSETS			
Property, plant and equipment	*11*	**5,003,774**	4,993,461
Right-of-use assets		**360,072**	374,056
Goodwill		**4,237,631**	4,252,618
Other intangible assets		**1,798,102**	1,684,510
Investments in joint ventures		**1,951**	637
Investments in associates		**519,638**	498,519
Equity investments designated at fair value through other comprehensive income		**724,154**	817,951
Prepayments, other receivables and other assets		**231,808**	326,756
Non-pledged time deposits	*13*	**868,231**	1,621,381
Deferred tax assets		**254,639**	295,917
Total non-current assets		**14,000,000**	14,865,806
CURRENT ASSETS			
Inventories		**902,817**	795,191
Trade and notes receivables	*12*	**1,490,704**	1,305,160
Prepayments, other receivables and other assets		**839,343**	741,138
Financial assets at fair value through profit or loss		**3,094,874**	3,769,187
Derivative financial instruments		**2,000**	8,547
Pledged deposits	*13*	**134,230**	178,568
Non-pledged time deposits	*13*	**1,642,318**	406,492
Cash and cash equivalents	*13*	**1,723,977**	2,142,651
Total current assets		**9,830,263**	9,346,934
CURRENT LIABILITIES			
Trade and bills payables	*14*	**217,250**	179,561
Other payables and accruals		**2,128,736**	1,721,896
Deferred income		**27,448**	27,131
Interest-bearing bank and other borrowings	*15*	**1,798,774**	2,243,750
Lease liabilities		**13,542**	15,269
Bonds payable	*16*	**—**	1,226,098
Tax payable		**17,353**	49,819
Total current liabilities		**4,203,103**	5,463,524
NET CURRENT ASSETS		**5,627,160**	3,883,410
TOTAL ASSETS LESS CURRENT LIABILITIES		**19,627,160**	18,749,216

	Notes	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
NON-CURRENT LIABILITIES			
Interest-bearing bank and other borrowings	*15*	**37,811**	37,628
Lease liabilities		**21,207**	31,660
Bonds payable	*16*	**—**	—
Deferred income		**378,885**	390,290
Deferred tax liabilities		**240,752**	248,835
Other non-current liabilities		**5,184**	4,473
Total non-current liabilities		**683,839**	712,886
Net assets		**18,943,321**	18,036,330
EQUITY			
Equity attributable to owners of the parent			
Share capital	*17*	**146**	146
Treasury shares		**(235,641)**	(235,641)
Share premium		**2,222,601**	2,729,341
Reserves		**14,332,287**	12,942,412
Equity attributable to owners of the parent		**16,319,393**	15,436,258
Non-controlling interests		**2,623,928**	2,600,072
Total equity		**18,943,321**	18,036,330

1. CORPORATE INFORMATION

3SBio Inc. was incorporated in the Cayman Islands as an exempted company with limited liability under the Cayman Islands Companies Laws on 9 August 2006. The registered office address of the Company is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**HKEx**") on 11 June 2015.

The Company is an investment holding company. During the six months ended 30 June 2025, the Company and its subsidiaries were principally engaged in the development, production, marketing and sale of biopharmaceutical products in the mainland area ("**Mainland China**") of the People's Republic of China (the "**PRC**").

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

2.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

The interim condensed consolidated financial information is presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand (RMB'000) except when otherwise indicated.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended IFRS Accounting Standard for the first time for the current period's financial information.

Amendments to IAS 21 *Lack of Exchangeability*

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

The Group has only one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.

Geographical information

(a) Revenue from external customers

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Mainland China	**4,215,107**	4,306,754
Others	**140,378**	82,691
Total revenue	**4,355,485**	4,389,445

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	30 June	31 December
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Mainland China	**10,059,737**	10,169,932
Others	**2,093,239**	1,960,625
Total non-current assets	**12,152,976**	12,130,557

The non-current asset information above is based on the locations of the assets and excludes financial instruments and deferred tax assets.

Information about major customers

The Group's customer base is diversified and no revenue from transactions with a significant customer accounted for 10% or more of the Group's total revenue during the reporting period.

4. REVENUE

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers		
Sale of biopharmaceuticals	**4,254,577**	4,332,185
Contract development and manufacturing operation business	**100,908**	57,260
Total	**4,355,485**	4,389,445

Disaggregated revenue information for revenue from contracts with customers

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Types of goods or services		
Sale of biopharmaceuticals	**4,254,577**	4,332,185
Contract development and manufacturing operation business	**100,908**	57,260
Total	**4,355,485**	4,389,445
Geographical markets		
Mainland China	**4,215,107**	4,306,754
Others	**140,378**	82,691
Total	**4,355,485**	4,389,445
Timing of revenue recognition		
Goods transferred at a point in time	**4,254,577**	4,332,185
Services transferred at a point in time	**100,908**	57,260
Total	**4,355,485**	4,389,445

5. OTHER INCOME AND GAINS

An analysis of other income and gains is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other income		
Interest income	**83,937**	81,224
Government grants related to		
— Assets	**14,948**	15,860
— Income	**28,381**	19,568
Others	**11,803**	12,967
Total other income	**139,069**	129,619
Gains		
Gain on disposal of a subsidiary	**2,614**	—
Gain on disposal of intangible asset	**79**	—
Foreign exchange differences, net	**9,515**	12,092
Fair value gains/(losses) on financial assets at fair value through profit or loss	**257,012**	(55,567)
Total gains	**269,220**	(43,475)
Total other income and gains	**408,289**	86,144

6. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cost of inventories sold	**564,704**	535,261
Cost of services provided	**74,976**	56,791
Depreciation of items of property, plant and equipment	**163,933**	122,759
Amortisation of other intangible assets	**57,836**	53,361
Depreciation of right-of-use assets	**12,837**	11,269
Amortisation of long-term deferred expenses	**7,089**	9,069
Employee benefit expenses	**810,218**	773,934
Equity-settled compensation expenses	**59,856**	—
Other expenses and losses:		
Donation	**4,061**	17,531
Loss on termination of a lease	**236**	—
Loss on disposal of items of property, plant and equipment	**8,333**	12,533
(Reversal of provision)/provision for impairment of trade receivables	**(1,933)**	799
Provision for impairment of prepayments, other receivables and other assets	**5,717**	4,494
Others	**9,052**	5,330
Total	**25,466**	40,687

7. FINANCE COSTS

An analysis of finance costs is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Interest on bank borrowings	**27,824**	77,661
Interest on bonds payable	**24,307**	25,132
Interest on lease liabilities	**871**	1,558
Total	**53,002**	104,351

8. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and/or operate.

Pursuant to the relevant rules and regulations of the Cayman Islands and the British Virgin Islands ("**BVI**"), the Company and the subsidiaries of the Group incorporated therein are not subject to any income tax in the Cayman Islands and the BVI.

No provision for Hong Kong profits tax has been made for the six months ended 30 June 2025 as the Group had no assessable profits arising in Hong Kong.

Under the relevant PRC income tax law, except for Shenyang Sunshine Pharmaceutical Co., Ltd. ("**Shenyang Sunshine**"), Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd. ("**Sciprogen**"), Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. ("**Sunshine Mandi**"), National Engineering Research Center of Antibody Medicine ("**NERC**") and Sunshine Guojian which enjoy certain preferential treatments available to the Group, the PRC subsidiaries of the Group are subject to income tax at a rate of 25% on their respective taxable income.

In accordance with the relevant Italian tax regulations, Sirton Pharmaceuticals S.p.A. ("**Sirton**") is subject to income tax at a rate of 27.9%.

Shenyang Sunshine, Sciprogen, Sunshine Mandi, NERC and Sunshine Guojian, which are qualified as High and New Technology Enterprises, were entitled to a preferential income tax rate of 15% for the six months ended 30 June 2025.

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. However, a lower withholding tax rate may be applied if there is a tax treaty between the PRC and the jurisdiction of the foreign investors.

An analysis of the provision for tax in the interim condensed consolidated financial information is as follows:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current	**199,935**	308,218
Deferred	**33,188**	6,065
Total tax charge for the period	**233,123**	314,283

9. DIVIDENDS

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Final 2024 — Hong Kong Dollar ("**HKD**") 25 cents per share (Final 2023 — HKD25 cents per share)	**547,149**	551,834

A final dividend in respect of the year ended 31 December 2024 of HKD25 cents per share was proposed pursuant to a resolution passed by the Board on 25 March 2025 and was approved at the annual general meeting of the Company on 25 June 2025. The dividend had not been paid to the shareholders of the Company during the reporting period.

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit for the period attributable to ordinary equity holders of the parent of RMB1,358,204,000 for the six months ended 30 June 2025 (for the six months ended 30 June 2024: RMB1,089,942,000) and the weighted average number of ordinary shares of 2,397,136,743 (for the six months ended 30 June 2024: 2,429,790,687) of the Company outstanding during the period, as adjusted to reflect the issue of ordinary shares during the period.

The calculation of the diluted earnings per share amount is based on the profit for the period attributable to ordinary equity holders of the parent, adjusted to reflect the interest on the convertible bonds, where applicable (see below). The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise or conversion of all dilutive potential ordinary shares into ordinary shares.

The calculations of basic and diluted earnings per share are based on:

	For the six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	**1,358,204**	1,089,942

	Number of shares For the six months ended 30 June	
	2025	2024
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of ordinary shares outstanding during the reporting period used in the basic earnings per share calculation	**2,397,136,743***	2,429,790,687
Effect of dilution — weighted average number of ordinary shares:		
Share options	**4,902,710**	—
Awarded shares	**43,107,688**	2,750,000
Total	**2,445,147,141**	2,432,540,687

* The weighted average number of shares was after taking into account the effect of treasury shares held.

11. PROPERTY, PLANT AND EQUIPMENT

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Carrying amount at 1 January	**4,993,461**	4,692,152
Additions	**167,631**	591,493
Depreciation provided during the period/year	**(163,933)**	(259,729)
Disposals	**(11,726)**	(23,651)
Exchange realignment	**18,341**	(6,804)
Carrying amount at 30 June/31 December	**5,003,774**	4,993,461

A freehold land with a carrying amount of approximately RMB2,938,000 as at 30 June 2025 (31 December 2024: RMB2,631,000) is located in Italy.

The Group is in the process of applying for the title certificates for certain of its buildings with an aggregate book value of approximately RMB9,511,000 as at 30 June 2025 (31 December 2024: RMB38,316,000). The directors are of the view that the Group is entitled to lawfully and validly occupy and use the above-mentioned buildings. The directors are also in the opinion that the aforesaid matter did not have any significant impact on the Group's financial position as at 30 June 2025.

At 30 June 2025, certain of the Group's freehold land and buildings with aggregate carrying amounts of RMB2,938,000 (31 December 2024: RMB2,631,000) and RMB33,143,000 (31 December 2024: RMB30,584,000), respectively, were pledged to secure general banking facilities granted to the Group (note 15).

12. TRADE AND NOTES RECEIVABLES

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables	**1,462,346**	1,312,969
Notes receivables	**79,808**	45,574
Total	**1,542,154**	1,358,543
Provision for impairment of trade receivables	**(51,450)**	(53,383)
Net carrying amount	**1,490,704**	1,305,160

The Group's trading terms with its customers are mainly on credit. The credit period is generally two months, extending up to three months for major customers. The Group seeks to maintain strict control over its outstanding receivables and overdue balances, which are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. Trade receivables are non-interest-bearing.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 1 year	**1,403,616**	1,260,527
1 to 2 years	**12,188**	7,530
Over 2 years	**46,542**	44,912
Total	**1,462,346**	1,312,969

13. CASH AND CASH EQUIVALENTS AND PLEDGED DEPOSITS

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Cash at bank and on hand	**1,413,284**	1,618,397
Restricted cash	**310,693**	524,254
Non-pledged time deposits	**868,231**	1,621,381
Time deposits with original maturity of more than three months	**1,642,318**	406,492
Pledged deposits	**134,230**	178,568
Subtotal	**4,368,756**	4,349,092
Less:		
Pledged deposits	**(134,230)**	(178,568)
Non-pledged time deposits	**(868,231)**	(1,621,381)
Cash and bank balances	**3,366,295**	2,549,143
Less:		
Time deposits with original maturity of more than three months	**(1,642,318)**	(406,492)
Cash and cash equivalents	**1,723,977**	2,142,651

The RMB is not freely convertible into other currencies. However, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, and Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business. The remittance of funds out of Mainland China is subject to exchange restrictions imposed by the PRC government.

The Group's cash and cash equivalents and deposits as at 30 June 2025 are denominated in the following currencies:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Denominated in:		
— RMB	**2,657,932**	2,953,324
— HKD	**63,985**	39,986
— United States Dollar ("**USD**")	**1,472,441**	1,211,301
— Euro ("**EUR**")	**174,157**	144,315
— Japanese Yen ("**JPY**")	**15**	2
— Australian Dollar ("**AUD**")	**226**	163
— Great Britain Pound ("**GBP**")	**—**	1
Total	**4,368,756**	4,349,092

Cash at banks earns interest at floating rates based on daily bank deposit rates. The bank balances and deposits are deposited with creditworthy banks with no recent history of default.

The carrying amounts of the cash and cash equivalents approximated to their fair values as at the end of the reporting period. Deposits of approximately RMB134,230,000 (31 December 2024: RMB178,568,000) have been pledged to secure letters of credit, bank acceptance bills and pending lawsuits and arbitration as at 30 June 2025.

14. TRADE AND BILLS PAYABLES

An ageing analysis of the trade and bills payables as at the end of the reporting period, based on the invoice date, is as follows:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 3 months	**162,070**	152,171
3 to 6 months	**49,132**	24,752
Over 6 months	**6,048**	2,638
Total	**217,250**	179,561

The trade and bills payables are non-interest-bearing and repayable within the normal operating cycle or on demand.

15. INTEREST-BEARING BANK AND OTHER BORROWINGS

	30 June 2025 ***RMB'000*** **(Unaudited)**	31 December 2024 *RMB'000* (Audited)
Current		
Bank loans — unsecured	**400,239**	1,993,750
Bank loans — secured	**1,398,535**	250,000
Subtotal — current	**1,798,774**	2,243,750
Bonds payable *(note 16)*	**—**	1,226,098
Total — current	**1,798,774**	3,469,848
Non-current		
Bank loans — secured	**37,811**	37,628
Total — non-current	**37,811**	37,628
Total	**1,836,585**	3,507,476

	30 June 2025 ***RMB'000*** **(Unaudited)**	31 December 2024 *RMB'000* (Audited)
Analysed into:		
Bank loans and overdrafts repayable:		
Within one year or on demand	**1,798,774**	2,243,750
In the second year	**—**	—
In the third to ninth years, inclusive	**37,811**	37,628
Total	**1,836,585**	2,281,378

The Group's interest-bearing bank borrowings as at 30 June 2025 are denominated in the following currencies:

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Denominated in:		
— RMB	**1,798,774**	800,374
— HKD	**—**	721,367
— EUR	**37,811**	759,637
Total	**1,836,585**	2,281,378

Notes:

(a) For the six months ended 30 June 2025, the bank borrowings bore interest at fixed interest rates ranging from 1.70% to 2.75% (31 December 2024: 2.10% to 3.03%) per annum.

(b) Certain of the Group's bank borrowings are secured by mortgages over the Group's freehold land and buildings (note 11).

(c) The Group has entered into certain recourse factoring agreements with certain bank for financing purposes. As at 30 June 2025, trade receivables of RMB618,794,000 (31 December 2024: RMB251,803,000) had been transferred under recourse factoring agreements. Those trade receivables were derived from internal transactions within the Group and were eliminated in full on consolidation. In the opinion of the directors, such transactions did not qualify for derecognition of the relevant trade receivables and the loans received from the bank were accounted for as secured borrowings.

(d) The carrying amounts of the current bank borrowings approximate to their fair values.

16. BONDS PAYABLE

On 26 June 2023, the Company issued unsecured non-listed bonds in an aggregate amount of RMB1,200,000,000 (the "**Panda Bonds**"). The bonds were priced at par at RMB100 each, carrying interest at a fixed rate of 4.20% per annum. The Company repaid the bonds on 25 June 2025.

	30 June 2025	31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Bonds payable	**—**	1,226,098
Amount repayable:		
Within one year	**—**	1,226,098

17. SHARE CAPITAL

Shares	30 June 2025 *RMB'000* (Unaudited)	31 December 2024 *RMB'000* (Audited)
Issued and fully paid:		
2,399,586,412 (31 December 2024: 2,395,573,912) ordinary shares	**146**	146

A summary of movements in the Company's issued share capital for the six months ended 30 June 2025 is as follows:

	Number of shares in issue	Share capital *RMB'000* (Unaudited)	Share premium *RMB'000* (Unaudited)	Total *RMB'000* (Unaudited)
Ordinary shares of USD0.00001 each at 31 December 2024 and 1 January 2025	**2,395,573,912**	**146**	**2,729,341**	**2,729,487**
Shares issued upon exercise of share option	**4,012,500**	**—***	**40,409**	**40,409**
Final 2024 dividend declared *(Note 9)***	**—**	**—**	**(547,149)**	**(547,149)**
Ordinary shares of USD0.00001 each at 30 June 2025	**2,399,586,412**	**146**	**2,222,601**	**2,222,747**

	Number of shares in issue	Share capital *RMB'000* (Audited)	Share premium *RMB'000* (Audited)	Total *RMB'000* (Audited)
Ordinary shares of USD0.00001 each at 31 December 2023 and 1 January 2024	2,438,920,412	149	3,517,283	3,517,432
Shares cancelled	(43,346,500)	(3)	(242,640)	(242,643)
Final 2023 dividend declared	—	—	(545,302)	(545,302)
Ordinary shares of USD0.00001 each at 31 December 2024	2,395,573,912	146	2,729,341	2,729,487

* The increase in share capital resulting from share option exercises in the six months ended 30 June 2025 was less than RMB1,000.

** The Company declared the final 2024 dividend out of the Company's share premium account.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review

Overview

3SBio is a leading biotechnology company in the PRC. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing and marketing bio-pharmaceuticals. The core commercialized products of the Group include several bio-pharmaceutical drugs, TPIAO (特比澳), recombinant human erythropoietin ("**rhEPO**") products EPIAO (益比奧) and SEPO (賽博爾), Yisaipu (益賽普) and Cipterbin (賽普汀), and a small molecule drug, Mandi (蔓迪). TPIAO is the only commercialized recombinant human thrombopoietin ("**rhTPO**") product in the world. According to IQVIA[1], the market share in the treatment of thrombocytopenia of TPIAO in Mainland China was 63.0% in the first half of 2025 in terms of sales value. With its two rhEPO products, the Group has been the premier market leader in the Mainland China rhEPO market for over two decades, holding a total market share of 41.5% in the first half of 2025. Yisaipu is the first-to-market Tumour Necrosis Factor ("**TNF**") α inhibitor product in Mainland China. Mandi has a dominant position in the Mainland China minoxidil market. The Group has been expanding its therapeutic coverage by adding products through internal research and development ("**R&D**") and various external strategic partnerships.

Key Events

Cooperation with Duality Biologics in respect of HER2 ADC Drug

As announced on 13 January 2025, Shenyang Sunshine, a wholly-owned subsidiary of the Company, and its subsidiaries entered into a cooperation agreement with Duality Biologics (Shanghai) Co., Ltd. ("**Duality Biologics**"), a clinical-stage innovative biopharmaceutical company focusing on the R&D of next-generation ADC therapeutic agents for patients suffering from cancers and autoimmune diseases, in respect of a HER2 ADC drug DB-1303. Pursuant to the agreement, Shenyang Sunshine will obtain the commercialization right of the HER2 ADC drug DB-1303 developed by Duality Biologics for various indications in Mainland China, Hong Kong and Macau. Shenyang Sunshine will pay Duality Biologics an initial payment as well as R&D and sales milestone payments in accordance with the agreement. Meanwhile, Duality Biologics will continue to be responsible for the clinical development, registration and other works of the relevant indications in the cooperation regions.

707 Injection Granted Breakthrough Therapy Designation by NMPA

On 17 April 2025, the anti-vascular endothelial growth factor ("**VEGF**")/programmed cell death protein 1 ("**PD-1**") bispecific antibody ("**BsAb**") (Group R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("**BTD**") by the National Medical Products Administration ("**NMPA**") of the PRC. The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("**NSCLC**").

[1] All market share information throughout this announcement cites the IQVIA data, unless otherwise noted.

707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in Mainland China, including a phase III clinical study for the first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC already approved by the Center for Drug Evaluation ("**CDE**") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in Mainland China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration ("**FDA**") in relation to its Investigational New Drug ("**IND**") application.

The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting an New Drug Application ("**NDA**"), if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process.

707 Out-license to Pfizer

— License Agreement

On 19 May 2025, the Company, Shenyang Sunshine and Pfizer Inc. ("**Pfizer**") have entered into an exclusive licensing agreement (the "**License Agreement**"). Sunshine Guojian will also join as a signing party through a joinder agreement.

Pursuant to the License Agreement, the Company and Shenyang Sunshine will grant an exclusive license to Pfizer to develop, manufacture, commercialize, and otherwise exploit the Group's breakthrough PD-1/VEGF bispecific antibody 707 worldwide excluding Mainland China (the "**Licensed Territory**"). The Company and Shenyang Sunshine will retain the development, manufacturing, commercialization, and other exploitation rights of 707 within Mainland China. Pfizer will have the option of commercialization rights in Mainland China.

Pfizer shall be responsible for bearing all costs of the development and regulatory affairs for all future trials of 707 in the Licensed Territory.

Pursuant to the License Agreement, the Group shall receive an upfront payment of USD1,250 million and may receive potential payments totaling up to USD4,800 million, including development, regulatory approval and sales milestone payments. All such payments are non-refundable and non-creditable. The Group will also receive a tiered double-digit percentage of royalties on net product sales in the Licensed Territory.

The License Agreement has come into effect on 24 July 2025.

For further details, please refer to the Company's announcements dated 20 May 2025 and 24 July 2025.

— Option Agreement

The Option Agreement has also come into effect as of 24 July 2025. The Option Agreement grants Pfizer an exclusive option to develop and commercialize 707 in the PRC. The Group will receive non-refundable and non-creditable option fee and exercise fee totaling no more than USD150 million. Upon exercise of such option as contemplated under the Option Agreement, the licensed territory under the License Agreement will be worldwide. The Group retains the right to supply 707 pursuant to the Clinical Supply Agreement executed on 2 July 2025 and the Commercial Supply Agreement to be negotiated if Pfizer exercises the option under the Option Agreement.

For further details, please refer to the Company's announcements dated 20 May 2025 and 24 July 2025.

— Subscription of New Shares by Pfizer

On 24 July 2025, the Company entered into a subscription agreement with Pfizer. Completion of the subscription took place on 1 August 2025. A total of 31,142,500 ordinary shares ("**Pfizer Shares**") have been successfully issued to Pfizer at the subscription price of HKD25.2055 per share. The Pfizer Shares represent (i) approximately 1.30% of the issued share capital of the Company immediately before completion; and (ii) approximately 1.28% of the issued share capital of the Company as enlarged by the issue and allotment of the Pfizer Shares.

The aggregate gross proceeds from the subscription amounted to approximately HKD785.0 million. The aggregate net proceeds from the subscription, after deduction of relevant costs and expenses, amounted to approximately HKD785.0 million. The Company intends to use (i) approximately HKD628.0 million (representing 80% of the net proceeds) for the global R&D arrangement of clinical and preclinical programs in the rich pipeline, as well as for enhancing manufacturing facilities; and (ii) approximately HKD157.0 million (representing 20% of the net proceeds) for other general corporate purposes.

For further details, please refer to the Company's announcements dated 24 July 2025 and 1 August 2025.

Key Events after the Reporting Period

Please refer to the immediately preceding subsection "Subscription of New Shares by Pfizer" in the section headed "Key Events" in this announcement above.

Key Commercialized Products

TPIAO

TPIAO is the Group's self-developed proprietary product, and has been the only commercialized rhTPO product in the world since its launch in 2005. TPIAO has been approved by the NMPA for three indications: the treatment of chemotherapy-induced thrombocytopenia ("**CIT**"), immune thrombocytopenia ("**ITP**") and pediatric ITP. TPIAO has the advantages of higher efficacy, faster platelet recovery and fewer side effects as compared to alternative treatments for CIT and ITP.

TPIAO has been listed on the National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (《國家基本醫療保險、工傷保險和生育保險藥品目錄》) ("**NRDL**") as a Class B Drug for the treatment of CIT in patients with solid tumors or ITP since 2017. In the "*Guidelines of CSCO – Cancer Therapy Induced Thrombocytopenia (2024 version)*"[2], rhTPO is listed as a treatment choice with the highest level recommendation, the Grade I recommendation. According to the "*Adapted Guideline for the Diagnosis and Treatment of Primary Immune Thrombocytopenia for Chinese Children (2021)*"[3], rhTPO is the preferred choice among the conventional second line treatments. According to the "*Chinese Guideline on the Diagnosis and Management of Adult Primary Immune Thrombocytopenia (2020 version)*"[4], rhTPO is one of the primary treatments for ITP emergency cases and is the preferred choice in the second line treatments list for both ITP and ITP in pregnancy. In "*Consensus on the Clinical Diagnosis, Treatment, and Prevention of Chemotherapy-Induced Thrombocytopenia in China (2019 version)*"[5], rhTPO is one of the primary treatments for CIT. rhTPO has also received similar professional endorsements in several national guidelines and experts consensus on treating certain other diseases in Mainland China.

Future growth of TPIAO may be driven by: (i) the enhanced market position as for inpatients attributable to its safety and efficacy, and its continually supplanting traditional interleukin ("**IL**") platelet-raising drugs in clinical use; (ii) the continued increase in the number of hospitals covered; and (iii) the expansion of indications. In the first half of 2025, its market share for the treatment of thrombocytopenia in Mainland China was 30.1% in terms of sales volume and 63.0% in terms of sales value. In July 2024, the primary endpoint has been achieved in the trial of phase III clinical study of TPIAO in the treatment of patients with chronic liver disease ("**CLD**") related thrombocytopenia who are candidates for invasive surgery. 3SBio submitted a marketing application for this indication to the NMPA in August 2024 and the application was accepted.

2 Issued by the Chinese Society of Clinical Oncology ("**CSCO**")

3 Issued by the Subspecialty Group of Hematologic Diseases, the Society of Pediatrics, Chinese Medical Association (the "**CMA**"); the Editorial Board, Chinese Journal of Pediatrics

4 Issued by the Thrombosis and Hemostasis Group of the Chinese Society of Hematology of the CMA

5 Issued by the Society of Chemotherapy, China Anti-Cancer Association; and Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association

EPIAO

EPIAO is approved by the NMPA for the following three indications: the treatment of anemia associated with chronic kidney disease ("**CKD**"), the treatment of chemotherapy-induced anemia ("**CIA**"), and the reduction of allogeneic blood transfusion in surgery patients. rhEPO products has been listed on the NRDL as a Class B Drug for renal anemia since 2000, for CIA in patients with non-hematological malignancies since 2019, and, additionally, rhEPO products for the reduction of allogeneic blood transfusion in surgery patients also is under NRDL coverage since 2024. EPIAO has also been listed on the 2018 National Essential Drug List. EPIAO has consistently been the premier market leader in the Mainland China rhEPO market since 2002 in terms of both sales volume and sales value. The multi-center biosimilar clinical trials for EPIAO in Russia and Thailand were completed in 2021. These trials demonstrate that EPIAO has promising effectiveness and manageable safety in patients with end-stage renal disease on hemodialysis. EPIAO is in the process of registration in several countries in Asia, Africa, Europe, South and North America.

Yisaipu

Yisaipu (Recombinant Human TNF-α Receptor II: IgG Fc Fusion Protein for Injection), is a TNF-α inhibitor product. It was first launched in 2005 in Mainland China for rheumatoid arthritis ("**RA**"). Its indications were expanded to ankylosing spondylitis ("**AS**") and psoriasis in 2007. Yisaipu has been listed on the NRDL as a Class B Drug since 2017 for RA and for AS, each subject to certain medical prerequisites, and additionally, since 2019 for the treatment of adult patients with severe plaque psoriasis. Yisaipu is the first-to-market TNF-α inhibitor product in Mainland China that filled a gap among domestic peers in regard to the fully-human therapeutic antibody-drugs. Compared with competitors, the efficacy and safety of Yisaipu have been proven in the domestic market over two decades. In "*2018 China Rheumatoid Arthritis Treatment Guidance*", an authoritative document issued by the CMA, Yisaipu was adopted under 'TNF-α inhibitors' as one of the RA treatment options, and TNF-α inhibitors was deemed as a group of biological agents with relatively sufficient evidence and relatively wide adoption in treating RA. TNF-α inhibitors have been recommended in a number of professional guidelines, such as "*EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Anti-rheumatic Drugs: 2022 Update"*, *"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021"* and *"Recommendations for Diagnosis and Treatment of Ankylosing Spondylitis*"[6].

[6] Issued by Chinese Rheumatology Association of the CMA, Chin J Intern Med, August 2022, Vol. 61, No. 8

In 2025, the Group will continue to enhance the awareness and application of Yisaipu within the medical profession and market growth of rheumatic immune biological agents in key third and fourth tier cities, and meanwhile, actively expand the application of Yisaipu in different departments and fields including Chinese traditional medicine. The pre-filled syringe of Yisaipu, launched since 2023, improves patient convenience and enhances the overall market competitiveness of Yisaipu.

Cipterbin

Cipterbin (Inetetamab) is the first innovative anti-HER2 monoclonal antibody ("**mAb**") in Mainland China with the engineered Fc region and optimized production process. Sunshine Guojian independently developed this product based on its proprietary technology platform. It was approved by the NMPA in June 2020 for treatment of HER2-positive metastatic breast cancer in combination with chemotherapy. Cipterbin has been listed on the NRDL since 2020. Inetetamab has been included in several clinical guidelines and experts consensus, including "*Guidelines of CSCO – Breast Cancer (2024 edition)*" and "*Guidelines for Breast Cancer Diagnosis and Treatment by China Anti-Cancer Association (2024 edition)*". In addition, positive research progress has been made in the application of Cipterbin in early neo-adjuvant therapy, treatment of advanced HER2-positive breast cancer, and pan-HER2. These researches provide a strong scientific basis for Cipterbin in the treatment of breast cancer at different stages, and also provide new ideas for the treatment of other HER2-positive cancers.

Mandi

Mandi, generically known as minoxidil, was launched in 2001 as the first over-the-counter ("**OTC**") drug in Mainland China for androgenetic alopecia ("**AGA**") and alopecia areata. Minoxidil is the world's only topical OTC drug for male and female alopecia that is approved for marketing by the U.S. FDA as well as the NMPA. The topical minoxidil can promote hair growth through: (i) promoting angiogenesis to increase regional blood supply and dilate scalp vascular, so as to improve microcirculation; (ii) directly stimulating proliferation and differentiation of hair follicle epithelial cells to extend hair growth cycle; and (iii) regulating the balance between calcium ion and potassium ion. In the "*Guideline for Diagnosis and Treatment of Androgenetic Alopecia*" issued by Chinese Medical Doctor Association, minoxidil receives the highest endorsement level, as it is superior to other AGA treatments in terms of anti-alopecia and improvement effects and safety. In "*Chinese Experts Consensus on the Diagnosis and Treatment of Female Androgenetic Alopecia (2022 edition)*" (issued by the CMA), 5% minoxidil receives the highest endorsement level in female androgenetic alopecia (FAGA).

In the first half of 2025, Mandi still had a dominant position in the Mainland China minoxidil market. The Group believes that Mandi's continuous growth in the future will be driven by: (i) persistent market education, as the Group will continue to invest resources in promotion and market education regarding the science of hair growth, enhancing the social recognition of Mandi as the top brand of scientific hair growth; (ii) professional digital marketing system, as Mandi expands its online layout from traditional e-commerce platforms such as Ali, JD, to new e-commerce platforms like TikTok store and Little Red Book, creating diversified and fine-tuned operation, accurately reaching and converting potential customers, and continuously boosting sales on e-commerce platforms; and (iii) launch of new SKUs of the brand.

CDMO Business

The Group's contract development and manufacturing operation ("**CDMO**") business currently comprises Northern Medicine Valley Desen (Shenyang) Biologics Co., Ltd. ("**Desen Biologics**"), Shanghai Shengguo Pharmaceutical Development Co., Ltd., Guangdong Sunshine Pharmaceutical Co., Ltd. ("**Guangdong Sunshine**") and Sirton in Italy, all being the Group's subsidiaries. Among them, Desen Biologics has a total planned area of 500 Chinese mu, designed as a biopharmaceutical CDMO base, a manufacturing base of biopharmaceutical raw and auxiliary materials and consumables, and a biopharmaceutical core process equipment base that are domestically-leading, oriented to the international market and compliant with relevant Chinese, EU and U.S. Good Manufacturing Practice regulations. Guangdong Sunshine focuses on services in GCT (Gene and Cell Therapy).

Research and Development

The Group's integrated R&D platform covers a broad range of technical expertise in the discovery and development of various innovative large and small molecule products, including antibody discovery, molecular cloning, antibody/protein engineering, gene expression, cell line construction, manufacturing process development, pilot and large-scale manufacturing, quality control and assurance, design and management of pre-clinical and clinical trials, and regulatory filing and registration. The Group is well experienced in the R&D of mammalian cell-expressed, bacterial cell-expressed and chemically-synthesized pharmaceuticals.

The Group focuses its R&D efforts on researching and developing innovative biologicals. Currently, the Group has several leading biological products in various clinical development stages in the areas of nephrology, oncology, autoimmune and inflammatory diseases, ophthalmology, dermatological and metabolic diseases.

The Group's R&D team, consisting of nearly 800 experienced scientists, is working diligently to research and discover new medicines, to accelerate the progress of clinical development, and to bring breakthrough therapies to fulfill the unmet medical needs of patients.

Product Pipeline

As at 30 June 2025, amongst the 30 key product candidates within the Group's active pipeline, 27 were being developed as innovative drugs in Mainland China. 18 are antibodies, 6 are other biologic products, and 6 are small molecule drugs. The Group has 14 product candidates in hematology/oncology; 10 product candidates that target auto-immune diseases including plaque psoriasis, atopic dermatitis, gouty arthritis, etc., ophthalmic disease (branch retinal vein occlusion ("**BRVO**")), and other diseases; 3 product candidates in nephrology; 2 product candidates in dermatology and 1 product candidate in metabolic diseases.

Notes to R&D Pipeline Chart (below):

(1) Each arrow bar indicates the progress in Mainland China, other than those bearing remarks on U.S. progress.

(2) ANDA: abbreviated NDA

(3) The chart only displays the highest clinical stage of all the indications of a product candidate

R&D Pipeline



The Group has fully utilized its thirty years of experience in the R&D of biopharmaceuticals, and has deployed a number of early discovery projects in hematology, oncology and autoimmune fields, covering more than 10 innovative targets, which provide a long-term strategic reserve for the Group's R&D.

Key Product Developments

(Unless otherwise noted, this section headed "Key Product Developments" addresses the developments in Mainland China.)

— *New Drug Application*

NuPIAO (Second-generation rhEPO, SSS06): The Group completed the phase III clinical trial of SSS06 for the treatment of anemia in chronic renal failure. The NDA for this product submitted by the Group is being reviewed by the NMPA for the treatment of adult dialysis patients undergoing erythropoietin therapy. Moreover, the patient enrollment of the phase II clinical study of SSS06 targeting CIA is currently ongoing.

Anti-IL-17A mAb (608): The phase III clinical trial of 608 in patients with moderate-to-severe plaque psoriasis has successfully reached all efficacy endpoints, and the NDA was submitted and accepted in November 2024. The phase II clinical study of 608 for the treatment of patients with ankylosing spondylitis has completed and phase III clinical trial is expected to commence in 2025, while patient enrollment in the phase II clinical trial for patients with non-radiographic axial spondylitis is completed.

Anti-IL-1 β mAb (613): Phase III clinical trial of 613 for the treatment of acute gouty arthritis (AG) has been completed and the NDA was submitted and accepted in June 2025. Additionally, the phase II clinical trial treating patients in the intermittent phase of gouty arthritis (PFG) has been completed.

— *Phase III development*

Anti-VEGF mAb (601A): The Group has completed the phase III clinical trial of 601A for BRVO, and expects to submit the marketing application in 2025.

Clascoterone (WS204): Patient recruitment for the phase III bridging clinical trial of WS204 for treatment of moderate-to-severe acne vulgaris has been completed, and the Group plans to complete the clinical trial in 2025 and submit the marketing application.

Anti-IL-4R α mAb (611): The phase III clinical trial of 611 in adult patients with atopic dermatitis has successfully reached primary endpoints. The patient enrollment for the phase III clinical trial for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) has been completed. The phase II clinical trial of 611 for moderate-to-severe Chronic Obstructive Pulmonary Disease has been completed, and the phase III clinical trial of the product is currently ongoing. Furthermore, the phase II clinical trial of 611 in adolescent AD indication has been completed with positive results, and the phase III clinical trial of the product is currently ongoing, while the phase Ib clinical trial for children with moderate-to-severe AD has been completed, and the patient enrollment for the phase II clinical trial is currently ongoing.

Anti-IL-5 mAb (610): The patient enrollment for phase III clinical trial of 610 for the treatment of severe eosinophilic asthma is currently ongoing, with phase II data indicating positive efficacy outcomes.

Semaglutide Injection: Patient enrollment for the phase III clinical trial of the Group's collaborative product, Semaglutide Injection in weight management indication, was completed in February 2025 by the partner, Hybio Pharmaceutical Co., Ltd. Currently, in accordance with the "*Guidelines for Design of Clinical Trials for Biosimilar Semaglutide Injection in Weight Management Indication*" issued by the CDE, the 44-week drug administration treatment is underway, to be followed by data evaluation and the marketing application process.

— *Phase II development*

HIF-117 (SSS17): The phase II clinical trial of SSS17 in non-dialysis patients with chronic renal anemia is being actively conducted. The Group plans to complete the phase II trial and commence the phase III trial in 2025. The application for the phase II clinical trial of SSS17 for the indication of postoperative anemia (POA) was approved by the CDE in April 2025, and it is being conducted. SSS17 is a selective small molecule inhibitor to hypoxia inducible factor ("**HIF**") proline hydroxylase (HIFPH), a molecule which can improve the stability and half-life period of HIF, so as to promote the secretion of erythropoietin (EPO). It is expected that SSS17 will have a synergistic effect with the Group's rhEPO injection drug in the future, providing patients with an alternative treatment option.

Anti-NGFAb (SSS40): It is a humanized nerve-growth factor (NGF) mAb. The Group is currently conducting the patient enrollment for the phase II clinical trial of SSS40 for the treatment of patients with moderate-to-severe bone metastasis cancer pain.

Anti-PD-1/HER2 BsAb (705): It is an anti-PD-1/HER2 BsAb independently developed by the Group. It simultaneously inhibits the PD-1/PD-L1 signaling pathway and the HER2 signaling pathway, integrating the mechanisms of action of targeted therapy and immunotherapy, thus having the potential to achieve enhanced tumor immune surveillance. The patient enrollment for the phase II clinical trial of 705 for HER-2 positive advanced solid tumors is currently ongoing in Mainland China; the IND application of 705 has been approved by the U.S. FDA.

Anti-PD-1/PD-L1 BsAb (706): It is an anti-PD-1/PD-L1 BsAb independently developed by the Group. It simultaneously targets PD-1 and PD-L1 and can effectively avoid the mismatch of BsAb with good physicochemical properties. The phase II clinical trial of 706 for advanced solid tumors is currently ongoing.

— *Phase I development and new IND applications*

Rapamycin Nanoparticle (SSS39): The phase I clinical trial of SSS39 is currently ongoing and it is expected to be completed in 2025. Rapamycin nanoparticle is a new type of macrolide immunosuppressant that can be co-administered with biological agents to induce immune tolerance, thereby reducing the immunogenicity of the biological agents and maintaining their efficacy.

Pegsiticase (SSS11): The Group has completed the phase Ib clinical trial for SSS11 in patients with high uric acid level and medical history of gout symptoms in Mainland China. The phase III clinical trial of the combination therapy SEL-212 for chronic refractory gout in the United States that the Group collaborates with its business partner Swedish Orphan Biovitrum AB (STO: SOBI) ("**Sobi**") has been completed. Sobi has submitted the rolling Biologics License Application (BLA) to the U.S. FDA in July 2024. SEL-212 contains pegsiticase (also known as pegadricase, a recombinant enzyme that metabolizes uric acid).

Anti-BDCA2 Ab (626): It is an anti-blood dendritic cell antigen 2 (BDCA2) antibody ("**Ab**") independently developed by Sunshine Guojian. The Group has completed patient enrollment for the phase Ia clinical trial of 626 for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) indications in Mainland China, with positive safety and PK/PD data. The U.S. IND application for these two indications has also been approved.

Anti-TL1A Ab (627): It is a tumor necrosis factor-like ligand 1A (TL1A) targeting mAb independently developed by Sunshine Guojian. The Group is enrolling patients for the phase I clinical trial of 627 for ulcerative colitis (UC) in Mainland China. The U.S. IND application for UC indication has also been approved by the U.S. FDA.

Anti-PD-1/TGF-β BsAb (708): It is an anti-PD-1/transforming growth factor β (TGF-β) BsAb independently developed by the Group. The phase I clinical trial of 708 for advanced solid tumors is currently ongoing.

Anti-MUC17/CD3/CD28 Tri-specific Ab (SSS59): It is a recombinant human anti-Mucin 17 (MUC17)/cluster of differentiation 3(CD3)/cluster of differentiation 28 (CD28) tri-specific Ab independently developed by the Group. The phase I clinical trial of SSS59 for advanced solid tumor is currently ongoing.

Anti-B7H3 Ab/IL15Rα-IL15 Fusion Proteins (SPGL008): It is B7H3 Ab/IL15Rα-IL15 Fusion proteins independently developed by the Group. The phase I clinical trial of SPGL008 for advanced solid tumor is currently ongoing.

Sales, Marketing and Distribution

The Group's sales and marketing efforts are characterized by a strong emphasis on academic promotion. The Group aims to promote and strengthen the Group's academic recognition and the brand awareness of its products among medical experts. The Group markets and promotes its key products mainly through its in-house team. The Group sells these products to distributors who are responsible for delivering products to hospitals and other medical institutions. Mandi is also sold through retail pharmacies and online stores.

As at 30 June 2025, the Group's extensive sales and distribution network in Mainland China was supported by 3,054 sales and marketing employees, thousands of distributors and third-party promoters. During the Reporting Period, the Group's products were sold in nearly 3,000 Grade III hospitals and nearly 7,000 Grade II or lower hospitals and medical institutions across all provinces, autonomous regions and special municipalities in Mainland China. In addition, TPIAO, Yisaipu, EPIAO, SEPO and some of the Group's other products are exported to a number of countries through international promoters. During the Reporting Period, the Group's products were sold in 20 countries, including Thailand, Brazil, the Philippines and Pakistan.

Outlook

Looking back on the first half of 2025, China's medical payment system underwent historic restructuring, transitioning from "a system with national health insurance as sole-payer" toward "multi-payers coordination integrating public and private coverages", thereby opening new reimbursement pathways for innovative drugs and medical devices. The National Healthcare Security Administration enhanced reimbursement support for innovative drugs and medical devices through establishing a comprehensive health insurance value assessment mechanism, optimizing pricing policies for innovative pharmaceuticals drugs and medical devices, and enabling data interoperability between medical insurance data and innovative drugs and medical device R&D. In July, the National Healthcare Security Administration formally released the *2025 Adjustment Plan for China's National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance and Commercial Health Insurance Reimbursement List for Innovative Drugs* (《2025年國家基本醫療保險、生育保險和工傷保險藥品目錄及商業健康保險創新藥品目錄調整工作方案》), establishing a tiered reimbursement pathway for innovative drugs. For the 11th batch of nationally organized centralized drug procurement announced in August, the National Healthcare Security Administration emphasized principles of "ensuring clinical stability, safeguarding quality, preventing bid rigging, and curbing malignant competition", moving away from simplistic reliance on the lowest bid. Amid these structural shifts in the reimbursement landscape, China's pharmaceutical industry is accelerating its transition toward innovation-driven and high-quality development.

Meanwhile, overseas multinational corporations are increasingly recognizing the quality of domestic innovative drugs. In the first half of 2025, the sum of China's innovative drug overseas licensing deals reached USD60.8 billion, surpassing the total for the entire 2024. The Group's bi-specific antibody product SSGJ-707 completed a transaction of over USD6 billion with Pfizer, with a record-breaking upfront payment of USD1.25 billion for Chinese innovative drug out-licensing deals; the potential total transaction consideration also set a new record among China's innovative drug global licensing deals. From one perspective, the Group's achievements reflect a historic shift in Chinese innovative drugs from "following and imitating the global industry" to "independent innovation and leading the global industry".

Looking ahead to the second half of 2025, the Group will continue accelerating early-discovery and clinical development of innovative drugs, concentrating more resources in areas with broad patient needs such as oncology, autoimmune diseases, and nephrology, to empower R&D teams in target discovery and drug development, focusing on improving efficacy and safety profiles of innovative drugs while expediting innovation pace and elevating innovation standards. In the commercialization field, the Group will advance market access and academic promotion for newly approved products including Teaisheng® (特艾升®) (Eltrombopag Suspension) and Liporaxel® (paclitaxel oral solution), actively upgrade team capabilities and build talent pipelines to prepare for upcoming commercialization opportunities from both self-developed and partnered innovative drugs. As for external collaborations, the Group will continue a dual-track strategy of internal R&D and external cooperation. It will explore innovative drug collaboration targets with potentials to complement the Company's existing product portfolio. Meanwhile, it will actively seek global partners to jointly promote the global development of pipeline products. The Group is committed to leveraging its mature capabilities in biopharmaceutical R&D, registration, commercial production, and sales to boost the R&D and launch process of more high-quality collaborative products. Driven by the mission of making innovative biopharmaceuticals accessible, the Group will accelerate the market launch of more high-quality products to benefit patients.

Financial Review

Revenue

For the Reporting Period, the Group's revenue amounted to approximately RMB4,355.5 million, as compared to approximately RMB4,389.4 million for the six months ended 30 June 2024, representing a decrease of approximately RMB33.9 million, or approximately 0.8%.

For the Reporting Period, the Group's sales of TPIAO decreased to approximately RMB2,371.2 million, as compared to approximately RMB2,475.9 million for the six months ended 30 June 2024, representing a decrease of approximately RMB104.7 million, or approximately 4.2%. The decrease was primarily attributable to a decrease in sales volume. For the Reporting Period, sales of TPIAO accounted for approximately 54.4% of the Group's total revenue.

For the Reporting Period, the Group's sales of EPIAO and SEPO decreased to approximately RMB455.4 million, as compared to approximately RMB515.7 million for the six months ended 30 June 2024, representing a decrease of approximately RMB60.3 million, or approximately 11.7%. The decrease was mainly due to decreases in both the sales price and in sales volume. For the Reporting Period, the Group's sales of EPIAO decreased to approximately RMB345.6 million, as compared to approximately RMB393.1 million for the six months ended 30 June 2024, representing a decrease of approximately RMB47.5 million, or approximately 12.1%. For the Reporting Period, the Group's sales of SEPO decreased to approximately RMB109.8 million, as compared to approximately RMB122.6 million for the six months ended 30 June 2024, representing a decrease of approximately RMB12.8 million, or approximately 10.4%. For the Reporting Period, the combined sales of EPIAO and SEPO accounted for a total of approximately 10.5% of the Group's total revenue.

For the Reporting Period, the Group's sales from alopecia area increased to approximately RMB689.9 million, as compared to approximately RMB557.2 million for the six months ended 30 June 2024, representing an increase of approximately RMB132.7 million, or approximately 23.8%. The increase was mainly attributable to the increased market demand for hair loss and growth treatments, which was driven by the Group's diversified and effective promotional efforts. For the Reporting Period, the Group's sales of Mandi increased to approximately RMB681.5 million, as compared to approximately RMB549.8 million for the six months ended 30 June 2024, representing an increase of approximately RMB131.7 million, or approximately 24.0%. For the Reporting Period, the sales from alopecia area accounted for a total of approximately 15.8% of the Group's revenue.

For the Reporting Period, the Group's revenue from CDMO business increased to approximately RMB100.9 million, as compared to approximately RMB57.3 million for the six months ended 30 June 2024, representing an increase of approximately RMB43.6 million, or approximately 76.1%. The increase was mainly attributable to the increased CDMO orders from customers.

For the Reporting Period, the Group's other sales, primarily comprising sales from Yisaipu, Cipterbin, Sparin (an injectable low-molecular-weight heparin calcium product indicated for: (i) prophylaxis and treatment of deep vein thrombosis; and (ii) prevention of clotting during hemodialysis), export sales and other products, decreased to approximately RMB770.8 million, as compared to approximately RMB805.0 million for the six months ended 30 June 2024, representing a decrease of approximately RMB34.2 million, or approximately 4.2%.

Cost of Sales

The Group's cost of sales increased from approximately RMB592.1 million for the six months ended 30 June 2024 to approximately RMB639.7 million for the Reporting Period, which accounted for approximately 14.7% of the Group's total revenue for the same period. The primary reason for the increase in the Group's cost of sales was mainly attributable to the increased sales volume of high-cost products for the Reporting Period, as compared to the corresponding period in 2024.

Gross Profit

For the Reporting Period, the Group's gross profit decreased to approximately RMB3,715.8 million, as compared to approximately RMB3,797.4 million for the six months ended 30 June 2024, representing a decrease of approximately RMB81.6 million, or approximately 2.1%. The Group's gross profit margin decreased to approximately 85.3% for the Reporting Period from approximately 86.5% for the corresponding period in 2024.

Other Income and Gains

The Group's other income and gains mainly comprised government grants, interest income, foreign exchange gain, fair value gain or loss on financial assets at FVTPL and other miscellaneous income. For the Reporting Period, the Group's other income and gains increased to approximately RMB408.3 million, as compared to approximately RMB86.1 million for the six months ended 30 June 2024, representing an increase of approximately RMB322.2 million. The increase was mainly attributable to the fair value changes on financial assets at FVTPL during the Reporting Period.

Selling and Distribution Expenses

The Group's selling and distribution expenses primarily consisted of marketing and promotion expenses, staff costs, and other miscellaneous selling and distribution expenses. For the Reporting Period, the Group's selling and distribution expenses amounted to approximately RMB1,615.9 million, as compared to approximately RMB1,594.0 million for the six months ended 30 June 2024, representing an increase of approximately RMB21.9 million, or approximately 1.4%. In terms of the percentage of revenue, the Group's selling and distribution expenses increase from approximately 36.3% for the six months ended 30 June 2024 to approximately 37.1% for the Reporting Period.

Administrative Expenses

The Group's administrative expenses consisted of staff costs, professional fees, depreciation and amortization, property expenses, share-based compensation, and other miscellaneous administrative expenses. For the Reporting Period, the Group's administrative expenses amounted to approximately RMB283.4 million, as compared to approximately RMB201.2 million for the six months ended 30 June 2024, representing an increase of approximately RMB82.2 million, or approximately 40.9%. The increase was mainly attributable to the increased share-based compensation. The administrative expenses as a percentage of revenue represented approximately 6.5% for the Reporting Period and approximately 4.6% for the six months ended 30 June 2024.

R&D Costs

The Group's R&D costs primarily consisted of staff costs, materials consumption, clinical trials costs, depreciation and amortisation, and other miscellaneous R&D expenses. For the Reporting Period, the Group's R&D costs amounted to approximately RMB547.5 million, as compared to approximately RMB476.2 million for the six months ended 30 June 2024, representing an increase of approximately RMB71.3 million, or approximately 15%. The increase was mainly due to the speed-up of the Group's R&D projects. The R&D costs accounted for approximately 12.6% of revenue for the Reporting Period, as compared to approximately 10.8% for the corresponding period in 2024.

Other Expenses and Losses

The Group's other expenses and losses primarily consisted of donation expenses, provision for impairment of financial assets, losses on disposal of items of property, plant and equipment, and other miscellaneous expenses and losses. For the Reporting Period, the Group's other expenses and losses amounted to approximately RMB25.5 million, as compared to approximately RMB40.7 million for the six months ended 30 June 2024, representing a decrease of approximately RMB15.2 million. The decrease was mainly due to the decrease in donation expenses.

Finance Costs

For the Reporting Period, the Group's finance costs amounted to approximately RMB53.0 million, as compared to approximately RMB104.4 million for the six months ended 30 June 2024, representing a decrease of approximately RMB51.4 million, or approximately 49.2%. The decrease was mainly due to the decreased interest-bearing bank borrowings for the Reporting Period.

Income Tax Expense

For the Reporting Period, the Group's income tax expense amounted to approximately RMB233.1 million, as compared to approximately RMB314.3 million for the six months ended 30 June 2024, representing a decrease of approximately RMB81.2 million, or approximately 25.8%. The effective tax rates for the Reporting Period and the corresponding period in 2024 were 14.4% and 22.1%, respectively. The decrease in effective tax rate was mainly due to the decrease in non-deductible expenses for the Reporting Period, as compared to those incurred in the six months ended 30 June 2024.

EBITDA and Net Profit Attributable to Owners of the Parent

The EBITDA for the Reporting Period increased by approximately RMB191.0 million or approximately 11.6% to approximately RMB1,832.5 million, as compared to approximately RMB1,641.5 million for the six months ended 30 June 2024. The EBITDA adjusted for non-operating items is defined as the EBITDA for the period excluding the Excluded Items. The Group's EBITDA adjusted for non-operating items for the Reporting Period decreased by approximately RMB53.8 million or approximately 3.2% to approximately RMB1,610.1 million, as compared to approximately RMB1,663.9 million for the six months ended 30 June 2024.

The net profit attributable to owners of the parent for the Reporting Period was approximately RMB1,358.2 million, as compared to approximately RMB1,089.9 million for the six months ended 30 June 2024, representing an increase of approximately RMB268.3 million, or approximately 24.6%. The net profit attributable to owners of the parent adjusted for non-operating items is defined as the profit for the period excluding the Excluded Items. The Group's net profit attributable to owners of the parent adjusted for non-operating items for the Reporting Period was approximately RMB1,135.8 million, as compared to approximately RMB1,112.4 million for the six months ended 30 June 2024, representing an increase of approximately RMB23.4 million, or approximately 2.1%.

Earnings Per Share

The basic earnings per share for the Reporting Period was approximately RMB0.57, as compared to approximately RMB0.45 for the six months ended 30 June 2024, representing an increase of approximately 26.7%.

Financial Assets Measured at Fair Value

As at 30 June 2025, financial assets measured at fair value primarily comprised the investment in treasury or cash management products issued by certain banks, the investments in listed companies and the investments in private equity funds which focus on investment in health-care industry.

The treasury or cash management products subscribed by the Group for treasury management purposes from time to time during the Reporting Period included wealth management products offered by various independent commercial banks. For further information, please refer to the section headed "Management Discussion and Analysis – Liquidity, Financial and Capital Resources – Significant Investments Held" below, which relates the Group's subscriptions from independent commercial banks.

Liquidity, Financial and Capital Resources

The Group's liquidity remained strong. For the Reporting Period, the Group's operating activities generated a net cash inflow of approximately RMB969.6 million, as compared to approximately RMB1,092.7 million for the six months ended 30 June 2024, representing a decrease of RMB123.1 million or approximately 11.3%. The decrease was mainly attributable to the increase in other cash payments relating to operating activities. As at 30 June 2025, the Group's cash and cash equivalents, non-pledged time deposits and pledged deposits were approximately RMB4,368.8 million.

Net Current Assets

As at 30 June 2025, the Group had net current assets of approximately RMB5,627.2 million, as compared to net current assets of approximately RMB3,883.4 million as at 31 December 2024. The current ratio of the Group was approximately 2.3 as at 30 June 2025, as compared to approximately 1.7 at 31 December 2024. The increase in net current assets and current ratio was mainly attributable to the lower current liabilities which was brought by the decrease in interest-bearing bank borrowings and the repayment of the Panda Bonds in 2025.

Funding and Treasury Policies, Borrowing and Pledge of Assets

The Group's finance department is responsible for the funding and treasury policies with regard to the overall business operation of the Group. The Company expects to fund its working capital and other capital requirements from a combination of various sources, including but not limited to internal financing and external financing at reasonable market rates. The Group continues to seek ways to improve the return of equity and assets while maintaining a prudent funding and treasury policy.

As at 30 June 2025, the Group had an aggregate interest-bearing bank borrowing of approximately RMB1,836.6 million, as compared to approximately RMB2,281.4 million as at 31 December 2024. The decrease in bank borrowings primarily reflected the repayment of loans of RMB2,602.0 million, partly offset by the additional bank-borrowings of approximately RMB2,100.0 million, during the Reporting Period. Among the short-term deposits, none was pledged to secure bank loans as at 30 June 2025.

As at 30 June 2025, the Group had no outstanding Panda Bonds, as compared to approximately RMB1,226.1 million as at 31 December 2024. For more information on the Group's Panda Bonds, please refer to Note 16 "BONDS PAYABLE" to the interim condensed consolidated financial information for the Reporting Period in this announcement above.

Gearing Ratio

The gearing ratio of the Group, which was calculated by dividing the total borrowings, lease liabilities and bonds by the total equity, decreased to approximately 9.9% as at 30 June 2025 from approximately 19.7% as at 31 December 2024. The decrease was primarily due to the repayment of the outstanding Panda Bonds during the Reporting Period.

Contingent Liabilities

As at 30 June 2025, the Group had no significant contingent liabilities.

Contractual Obligations

The Group's capital commitment amounted to approximately RMB876.1 million as at 30 June 2025, as compared to approximately RMB901.9 million as at 31 December 2024.

Foreign Exchange and Exchange Rate Risk

The Group mainly operates in Mainland China, with all material aspects of its regular business conducted in Renminbi other than: (i) the operations of Sirton; and (ii) the Group's exports, which amounted to approximately RMB58.6 million, or approximately 1.3% of the Group's revenue, for the Reporting Period. Except for the operations of Sirton, the Group's exports, potential international deal-making expenditures (such as expenditures related to international licensing and acquisitions), and foreign currency denominated bank borrowings and bank deposits, the Group believes that it does not have any other material direct exposure to foreign exchange fluctuations. As at 30 June 2025, the Group's foreign currency denominated bank deposits primarily comprised: (i) approximately USD205.7 million (equivalent to approximately RMB1,472.4 million); (ii) approximately HKD70.2 million (equivalent to approximately RMB64.0 million); and (iii) approximately EUR20.7 million (equivalent to approximately RMB174.2 million). The Group expects that the fluctuation of the Renminbi exchange rate will not have a material adverse effect on the operations of the Group in the foreseeable future.

Significant Acquisitions and Disposals

The Group did not have material acquisitions and disposals of subsidiaries, associates and joint ventures during the Reporting Period.

Significant Investments Held

As at 30 June 2025, the Group did not hold any significant investments. As at 30 June 2025, the Group held (i) equity investments designated at fair value through other comprehensive income of approximately RMB724.2 million; and (ii) wealth management products of various independent commercial banks as financial assets at FVTPL and derivative financial instruments of approximately RMB3,096.9 million, none of such investments, whether in any group of entities or products offered by any group of commercial banks, individually or in aggregate, represented 5.0% or more of the total assets of the Group.

Future Plans for Material Investments or Capital Assets

The Group estimates its total capital expenditure over the next three years will range from RMB800 million to RMB1,000 million. This expected capital expenditure will primarily be incurred for the maintenance of the Group's existing facilities and the expansion of its production capabilities. The Group expects to finance its capital expenditure through a combination of internally generated funds and bank borrowings.

EMPLOYEES AND EMOLUMENTS POLICY

As at 30 June 2025, the Group employed a total of 6,268 employees, as compared to a total of 5,577 employees as at 31 December 2024. Staff costs, including Directors' emoluments but excluding any contributions to the pension scheme, were approximately RMB809.8 million for the Reporting Period, as compared to approximately RMB721.9 million for the corresponding period in 2024. The Group generally structures its employees' remuneration package to include salary, bonus, equity compensation, and allowance elements. The compensation programs are designed to remunerate and reward the employees based on their performance, measured against specified objective criteria. The Group also provides welfare benefits in accordance with applicable regulations and its internal policies. Following the expiry of the share option scheme (adopted by the Company in May 2015) and the termination of the share award scheme (adopted by the Company in July 2019), the Company has adopted a share award scheme and a share option scheme in June 2025; and there are other incentive initiatives such as cash awards, all of which are for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. In addition, Sunshine Guojian adopted a restricted share incentive plan in February 2021 and there is also a gratuitous incentive scheme set up by founding and management members of the Group that serves to recognise employees' contributions.

INTERIM DIVIDEND

The Board did not recommend any interim dividend for the Reporting Period.

CORPORATE GOVERNANCE PRACTICES

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the shareholders of the Company and to enhance corporate value and accountability. The Company has applied the principles and code provisions as set out in the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**HKEx Listing Rules**") as its own code of corporate governance.

Except as expressly described below, the Company has complied with all the applicable code provisions set out in the CG Code during the Reporting Period.

Separation of the Roles of the Chairman of the Board and the Chief Executive Officer

Pursuant to code provision C.2.1 of the CG Code, companies listed on the HKEx are expected to comply with, but may choose to deviate from, the requirement that the responsibilities between the chairman and the chief executive officer should be segregated and should not be performed by the same individual. The Company does not have separate chairman and chief executive officer. Dr. LOU Jing currently performs these two roles. The Board believes that vesting both the roles of chairman and chief executive officer in the same person has the benefit of ensuring consistent leadership within the Group and facilitating a more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. In addition, all major decisions are made in consultation with members of the Board, including the relevant Board committees and independent non-executive Directors.

The Board will from time to time review and consider splitting the roles of chairman of the Board and the chief executive officer of the Company at an appropriate time, taking into account the circumstances of the Group as a whole.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS

The Company has adopted the "Model Code for Securities Transactions by Directors of Listed Issuer" as set out in Appendix C3 to the HKEx Listing Rules (the "**Model Code**") as its code of conduct regarding securities transactions by the Directors. Having made specific enquiry with the Directors, all Directors confirmed that they had complied with the required standards as set out in the Model Code during the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

There was no purchase, sale or redemption of any of the Company's listed securities (including sale of treasury shares (as defined under the HKEx Listing Rules)) by the Company or any of its subsidiaries during the Reporting Period.

AUDIT COMMITTEE

The Board has established an audit committee of the Company (the "**Audit Committee**"), which comprises the three independent non-executive Directors, namely Mr. PU Tianruo (chairman), Mr. NG Joo Yeow Gerry and Ms. YANG Hoi Ti Heidi.

The Audit Committee, together with the Board, has reviewed the unaudited condensed consolidated interim results of the Group for the Reporting Period. The Audit Committee has also reviewed the effectiveness of the risk management and internal control system of the Company and considers it to be effective and adequate.

SCOPE OF WORK OF ERNST & YOUNG

The financial information in the interim results announcement of the Group for the Reporting Period has been reviewed and agreed to by the Group's auditors, Ernst & Young, to the amounts set out in the Group's draft unaudited interim condensed consolidated financial information for the Reporting Period. The work performed by Ernst & Young in this respect did not constitute an assurance engagement in accordance with International Standards on Auditing, International Standards on Review Engagements or International Standards on Assurance Engagements issued by the International Auditing and Assurance Standards Board and consequently no assurance has been expressed by Ernst & Young on this interim results announcement.

PUBLICATION OF THE INTERIM RESULTS AND 2025 INTERIM REPORT ON THE WEBSITES OF THE HKEX AND THE COMPANY

This interim results announcement is published on the respective websites of the HKEx (www.hkexnews.hk) and the Company (www.3sbio.com).

The Company's 2025 interim report for the Reporting Period containing all the information required under the HKEx Listing Rules will be published on the respective websites of the HKEx and the Company in due course.

By Order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Hong Kong SAR, the PRC
29 August 2025

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive directors; Ms. ZHANG Jiaoe as non-executive director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi, and Mr. NG Joo Yeow Gerry as independent non-executive directors.